Skip to Content
Merck
CN
  • Voltage-independent GluN2A-type NMDA receptor Ca2+ signaling promotes audiogenic seizures, attentional and cognitive deficits in mice.

Voltage-independent GluN2A-type NMDA receptor Ca2+ signaling promotes audiogenic seizures, attentional and cognitive deficits in mice.

Communications biology (2021-01-10)
Ilaria Bertocchi, Ahmed Eltokhi, Andrey Rozov, Vivan Nguyễn Chi, Vidar Jensen, Thorsten Bus, Verena Pawlak, Marta Serafino, Hannah Sonntag, Boyi Yang, Nail Burnashev, Shi-Bin Li, Horst A Obenhaus, Martin Both, Burkhard Niewoehner, Frank N Single, Michael Briese, Thomas Boerner, Peter Gass, John Nick P Rawlins, Georg Köhr, David M Bannerman, Rolf Sprengel
ABSTRACT

The NMDA receptor-mediated Ca2+ signaling during simultaneous pre- and postsynaptic activity is critically involved in synaptic plasticity and thus has a key role in the nervous system. In GRIN2-variant patients alterations of this coincidence detection provoked complex clinical phenotypes, ranging from reduced muscle strength to epileptic seizures and intellectual disability. By using our gene-targeted mouse line (Grin2aN615S), we show that voltage-independent glutamate-gated signaling of GluN2A-containing NMDA receptors is associated with NMDAR-dependent audiogenic seizures due to hyperexcitable midbrain circuits. In contrast, the NMDAR antagonist MK-801-induced c-Fos expression is reduced in the hippocampus. Likewise, the synchronization of theta- and gamma oscillatory activity is lowered during exploration, demonstrating reduced hippocampal activity. This is associated with exploratory hyperactivity and aberrantly increased and dysregulated levels of attention that can interfere with associative learning, in particular when relevant cues and reward outcomes are disconnected in space and time. Together, our findings provide (i) experimental evidence that the inherent voltage-dependent Ca2+ signaling of NMDA receptors is essential for maintaining appropriate responses to sensory stimuli and (ii) a mechanistic explanation for the neurological manifestations seen in the NMDAR-related human disorders with GRIN2 variant-meidiated intellectual disability and focal epilepsy.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-β-Actin antibody produced in mouse, clone AC-15, ascites fluid
Sigma-Aldrich
Brij® L23, main component: tricosaethylene glycol dodecyl ether
Sigma-Aldrich
N-Methyl-D-aspartic acid, ≥98% (TLC), solid
Sigma-Aldrich
Anti-c-Fos (Ab-2) (4-17) Rabbit pAb, liquid, Calbiochem®
Sigma-Aldrich
Anti-PSD-95 Antibody, Chemicon®, from rabbit
Sigma-Aldrich
Monoclonal Anti-Parvalbumin antibody produced in mouse, clone PARV-19, ascites fluid
Sigma-Aldrich
Anti-Glutamate Receptor NMDAR2A (NR2A) antibody produced in rabbit, affinity isolated antibody, lyophilized powder
Sigma-Aldrich
Memantine hydrochloride, ≥98% (GC)
Sigma-Aldrich
Anti-Glutamate receptor 1 Antibody, from rabbit, purified by affinity chromatography
Sigma-Aldrich
Anti-c-Fos Antibody, from rabbit, purified by affinity chromatography